<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2019-05-20" updated="2019-11-23">
  <drugbank-id primary="true">DB15271</drugbank-id>
  <name>Crizanlizumab</name>
  <description>Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease.[L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. The genetic mutation associated with this disease leads to the formation of abnormal, sickle shaped red blood cells that aggregate and block blood vessels throughout the body, causing vaso-occlusive crises. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels.[T734]&#13;
&#13;
Currently, patients are prescribed [hydroxyurea] to raise levels of fetal hemoglobin as a method of reducing morbidity and mortality.[A187904] Though hydroxyurea has been shown to reduce the frequency of vaso-occlusive crises, adherence to this therapy is difficult due to adverse effects and the high variability of response to the drug between patients.[A187907] Crizanlizumab, or SEG101, is given once every 4 weeks and may improve patient adherence. It was developed by Novartis and was granted FDA approval on November 15, 2019.[L10097]</description>
  <cas-number>1690318-25-2</cas-number>
  <unii>L7451S9126</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A31470</ref-id>
        <pubmed-id>16478695</pubmed-id>
        <citation>Tabrizi MA, Tseng CM, Roskos LK: Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006 Jan;11(1-2):81-8. doi: 10.1016/S1359-6446(05)03638-X.</citation>
      </article>
      <article>
        <ref-id>A177074</ref-id>
        <pubmed-id>15389672</pubmed-id>
        <citation>Lobo ED, Hansen RJ, Balthasar JP: Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004 Nov;93(11):2645-68. doi: 10.1002/jps.20178.</citation>
      </article>
      <article>
        <ref-id>A187901</ref-id>
        <pubmed-id>27959701</pubmed-id>
        <citation>Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP: Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3.</citation>
      </article>
      <article>
        <ref-id>A187904</ref-id>
        <pubmed-id>12672732</pubmed-id>
        <citation>Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M: Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003 Apr 2;289(13):1645-51. doi: 10.1001/jama.289.13.1645.</citation>
      </article>
      <article>
        <ref-id>A187907</ref-id>
        <pubmed-id>31507334</pubmed-id>
        <citation>Riley TR, Riley TT: Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date. J Blood Med. 2019 Aug 30;10:307-311. doi: 10.2147/JBM.S191423. eCollection 2019.</citation>
      </article>
      <article>
        <ref-id>A187910</ref-id>
        <pubmed-id>30559624</pubmed-id>
        <citation>Gardner RV: Sickle Cell Disease: Advances in Treatment. Ochsner J. 2018 Winter;18(4):377-389. doi: 10.31486/toj.18.0076.</citation>
      </article>
      <article>
        <ref-id>A40006</ref-id>
        <pubmed-id>28653357</pubmed-id>
        <citation>Ryman JT, Meibohm B: Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588. doi: 10.1002/psp4.12224. Epub 2017 Jul 29.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T734</ref-id>
        <isbn/>
        <citation>Ankit Mangla; Moavia Ehsan; Smita Maruvada (2019). Sickle Cell Anemia. Stat Pearls.</citation>
      </textbook>
    </textbooks>
    <links>
      <link>
        <ref-id>L10097</ref-id>
        <title>FDA Approved Drug Products: Adakveo Crizanlizumab-TMCA Intravenous Injection</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Crizanlizumab is indicated to reduce the frequency of vaso-occlusive crisis in patients with sickle cell diseases who are â‰¥16 years old.[L10097]</indication>
  <pharmacodynamics>Crizanlizumab is a P-selectin inhibitor that prevents interactions between endothelial cells, platelets, red blood cells, and leukocytes.[L10097] It has a long duration of action as it is given every 4 weeks.[L10097] Patients should be counselled regarding the risk of infusion reactions as well as crizanlizumab's interference with platelet counts using EDTA tubes.[L10097]</pharmacodynamics>
  <mechanism-of-action>Crizanlizumab binds to P-selectin on endothelial cells and platelets, preventing their interaction with P-selectin glycoprotein ligand 1 on endothelial cells, platelets, red blood cells, and leukocytes.[A187910,L10097] By preventing this interaction, components of the blood are less likely to come together, causing a vaso-occlusive crisis in patients with sickle cell diseases.[A187910,L10097] The median per year incidence of vaso-occlusive crises was 1.04 in the high-dose crizanlizumab group, 2.00 in the low-dose crizanlizumab group, and 2.08 in the placebo group.[A187901]</mechanism-of-action>
  <toxicity>Data regarding the toxicity of crizanlizumab is not readily available.[L10097]</toxicity>
  <metabolism>Crizanlizumab is expected to be metabolized into smaller peptides and amino acids.[L10097]</metabolism>
  <absorption>Crizanlizumab reaches a C&lt;sub&gt;max&lt;/sub&gt; of 0.16mg/mL with an AUC of 34.6mg\*hr/mL.[L10097]</absorption>
  <half-life>Given a 5mg/kg dose of crizanlizumab, the mean terminal elimination half life of crizanlizumab is 10.6 days in healthy subjects and 7.6 days in patients with sickle cell disease.[L10097]</half-life>
  <protein-binding>Monoclonal antibodies are generally not protein bound[A31470,A177074].</protein-binding>
  <route-of-elimination>Monoclonal antibodies are eventually phagocytosed and broken down to smaller peptides and amino acids which are eliminated in a similar fashion to other proteins.[A31470,A177074] Monoclonal antibodies are generally not eliminated in the urine, and only a small amount is excreted in bile.[A40006]</route-of-elimination>
  <volume-of-distribution>The volume of distribution of crizanlizumab is 4.26L.[L10097]</volume-of-distribution>
  <clearance>Given a 5mg/kg dose of crizanlizumab, the clearance rate is 11.7ml/hr in healthy subjects.[L10097]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">crizanlizumab-tmca</synonym>
  </synonyms>
  <products>
    <product>
      <name>Adakveo</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0883</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA761128</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Adakveo</name>
      <ingredients>Crizanlizumab</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Antibodies, Monoclonal</category>
      <mesh-id>D000911</mesh-id>
    </category>
    <category>
      <category>Antibodies, Monoclonal, Humanized</category>
      <mesh-id>D061067</mesh-id>
    </category>
    <category>
      <category>Immunoglobulin G</category>
      <mesh-id>D007074</mesh-id>
    </category>
    <category>
      <category>Immunoglobulins</category>
      <mesh-id>D007136</mesh-id>
    </category>
    <category>
      <category>Serum Globulins</category>
      <mesh-id>D012712</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>10 mg/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties>
    <property>
      <kind>Molecular Weight</kind>
      <value>146000.0</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Crizanlizumab</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0001159</id>
      <name>P-selectin</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L10097</ref-id>
            <title>FDA Approved Drug Products: Adakveo Crizanlizumab-TMCA Intravenous Injection</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P16109" source="Swiss-Prot">
        <name>P-selectin</name>
        <general-function>Sialic acid binding</general-function>
        <specific-function>Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligand recognized is sialyl-Lewis X. Mediates rapid rolling of leukocyte rolling over vascular surfaces during the initial steps in inflammation through interaction with PSGL1.</specific-function>
        <gene-name>SELP</gene-name>
        <locus>1q22-q25</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>772-795</transmembrane-regions>
        <signal-regions>1-41</signal-regions>
        <theoretical-pi>6.64</theoretical-pi>
        <molecular-weight>90833.105</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10721</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SELP</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M60234</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>183389</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P16109</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>LYAM3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CD62 antigen-like family member P</synonym>
          <synonym>GMP-140</synonym>
          <synonym>GMRP</synonym>
          <synonym>Granule membrane protein 140</synonym>
          <synonym>GRMP</synonym>
          <synonym>LECAM3</synonym>
          <synonym>Leukocyte-endothelial cell adhesion molecule 3</synonym>
          <synonym>PADGEM</synonym>
          <synonym>Platelet activation dependent granule-external membrane protein</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016331|P-selectin
MANCQIAILYQRFQRVVFGISQLLCFSALISELTNQKEVAAWTYHYSTKAYSWNISRKYC
QNRYTDLVAIQNKNEIDYLNKVLPYYSSYYWIGIRKNNKTWTWVGTKKALTNEAENWADN
EPNNKRNNEDCVEIYIKSPSAPGKWNDEHCLKKKHALCYTASCQDMSCSKQGECLETIGN
YTCSCYPGFYGPECEYVRECGELELPQHVLMNCSHPLGNFSFNSQCSFHCTDGYQVNGPS
KLECLASGIWTNKPPQCLAAQCPPLKIPERGNMTCLHSAKAFQHQSSCSFSCEEGFALVG
PEVVQCTASGVWTAPAPVCKAVQCQHLEAPSEGTMDCVHPLTAFAYGSSCKFECQPGYRV
RGLDMLRCIDSGHWSAPLPTCEAISCEPLESPVHGSMDCSPSLRAFQYDTNCSFRCAEGF
MLRGADIVRCDNLGQWTAPAPVCQALQCQDLPVPNEARVNCSHPFGAFRYQSVCSFTCNE
GLLLVGASVLQCLATGNWNSVPPECQAIPCTPLLSPQNGTMTCVQPLGSSSYKSTCQFIC
DEGYSLSGPERLDCTRSGRWTDSPPMCEAIKCPELFAPEQGSLDCSDTRGEFNVGSTCHF
SCDNGFKLEGPNNVECTTSGRWSATPPTCKGIASLPTPGLQCPALTTPGQGTMYCRHHPG
TFGFNTTCYFGCNAGFTLIGDSTLSCRPSGQWTAVTPACRAVKCSELHVNKPIAMNCSNL
WGNFSYGSICSFHCLEGQLLNGSAQTACQENGHWSTTVPTCQAGPLTIQEALTYFGGAVA
STIGLIMGGTLLALLRKRFRQKDDGKCPLNPHSHLGTYGVFTNAAFDPSP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016332|P-selectin (SELP)
ATGGCCAACTGCCAAATAGCCATCTTGTACCAGAGATTCCAGAGAGTGGTCTTTGGAATT
TCCCAACTCCTTTGCTTCAGTGCCCTGATCTCTGAACTAACAAACCAGAAAGAAGTGGCA
GCATGGACTTATCATTACAGCACAAAAGCATACTCATGGAATATTTCCCGTAAATACTGC
CAGAATCGCTACACAGACTTAGTGGCCATCCAGAATAAAAATGAAATTGATTACCTCAAT
AAGGTCCTACCCTACTACAGCTCCTACTACTGGATTGGGATCCGAAAGAACAATAAGACA
TGGACATGGGTGGGAACCAAAAAGGCTCTCACCAACGAGGCTGAGAACTGGGCTGATAAT
GAACCTAACAACAAAAGGAACAACGAGGACTGCGTGGAGATATACATCAAGAGTCCGTCA
GCCCCTGGCAAGTGGAATGATGAGCACTGCTTGAAGAAAAAGCACGCATTGTGTTACACA
GCCTCCTGCCAGGACATGTCCTGCAGCAAACAAGGAGAGTGCCTCGAGACCATCGGGAAC
TACACCTGCTCCTGTTACCCTGGATTCTATGGGCCAGAATGTGAATACGTGAGAGAGTGT
GGAGAACTTGAGCTCCCTCAACACGTGCTCATGAACTGCAGCCACCCTCTGGGAAACTTC
TCTTTTAACTCGCAGTGCAGCTTCCACTGCACTGACGGGTACCAAGTAAATGGGCCCAGC
AAGCTGGAATGCTTGGCTTCTGGAATCTGGACAAATAAGCCTCCACAGTGTTTAGCTGCC
CAGTGCCCACCCCTGAAGATTCCTGAACGAGGAAACATGACCTGCCTTCATTCTGCAAAA
GCATTCCAGCATCAGTCTAGCTGCAGCTTCAGTTGTGAAGAGGGATTTGCATTAGTTGGA
CCGGAAGTGGTGCAATGCACAGCCTCGGGGGTATGGACAGCCCCAGCCCCAGTGTGTAAA
GCTGTGCAGTGTCAGCACCTGGAAGCCCCCAGTGAAGGAACCATGGACTGTGTTCATCCG
CTCACTGCTTTTGCCTATGGCTCCAGCTGTAAATTTGAGTGCCAGCCCGGCTACAGAGTG
AGGGGCTTGGACATGCTCCGCTGCATTGACTCTGGACACTGGTCTGCACCCTTGCCAACC
TGTGAGGCTATTTCGTGTGAGCCGCTGGAGAGTCCTGTCCACGGAAGCATGGATTGCTCT
CCATCCTTGAGAGCGTTTCAGTATGACACCAACTGTAGCTTCCGCTGTGCTGAAGGTTTC
ATGCTGAGAGGAGCCGATATAGTTCGGTGTGATAACTTGGGACAGTGGACAGCACCAGCC
CCAGTCTGTCAAGCTTTGCAGTGCCAGGATCTCCCAGTTCCAAATGAGGCCCGGGTGAAC
TGCTCCCACCCCTTCGGTGCCTTTAGGTACCAGTCAGTCTGCAGCTTCACCTGCAATGAA
GGCTTGCTCCTGGTGGGAGCAAGTGTGCTACAGTGCTTGGCTACTGGAAACTGGAATTCT
GTTCCTCCAGAATGCCAAGCCATTCCCTGCACACCTTTGCTAAGCCCTCAGAATGGAACA
ATGACCTGTGTTCAACCTCTTGGAAGTTCCAGTTATAAATCCACATGTCAATTCATCTGT
GACGAGGGATATTCTTTGTCTGGACCAGAAAGATTGGATTGTACTCGATCGGGACGCTGG
ACAGACTCCCCACCAATGTGTGAAGCCATCAAGTGCCCAGAACTCTTTGCCCCAGAGCAG
GGCAGCCTGGATTGTTCTGACACTCGTGGAGAATTCAATGTTGGCTCCACCTGCCATTTC
TCTTGTGACAACGGCTTTAAGCTGGAGGGGCCCAATAATGTGGAATGCACAACTTCTGGA
AGATGGTCAGCTACTCCACCAACCTGCAAAGGCATAGCATCACTTCCTACTCCAGGGGTG
CAATGTCCAGCCCTCACCACTCCTGGGCAGGGAACCATGTACTGTAGGCATCATCCGGGA
ACCTTTGGTTTTAATACCACTTGTTACTTTGGCTGCAACGCTGGATTCACACTCATAGGA
GACAGCACTCTCAGCTGCAGACCTTCAGGACAATGGACAGCAGTAACTCCAGCATGCAGA
GCTGTGAAATGCTCAGAACTACATGTTAATAAGCCAATAGCGATGAACTGCTCCAACCTC
TGGGGAAACTTCAGTTATGGATCAATCTGCTCTTTCCATTGTCTAGAGGGCCAGTTACTT
AATGGCTCTGCACAAACAGCATGCCAAGAGAATGGCCACTGGTCAACTACCGTGCCAACC
TGCCAAGCAGGACCATTGACTATCCAGGAAGCCCTGACTTACTTTGGTGGAGCGGTGGCT
TCTACGATAGGTCTGATAATGGGTGGGACGCTCCTGGCTTTGCTAAGAAAGCGTTTCAGA
CAAAAAGATGATGGGAAATGCCCCTTGAATCCTCACAGCCACCTAGGAACATATGGAGTT
TTTACAAACGCTGCATTTGACCCGAGTCCTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00084</identifier>
            <name>Sushi</name>
          </pfam>
          <pfam>
            <identifier>PF00059</identifier>
            <name>Lectin_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet alpha granule membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet dense granule membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>fucose binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glycosphingolipid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heparin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lipopolysaccharide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oligosaccharide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sialic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium-mediated signaling using intracellular calcium source</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to Gram-negative bacterium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukocyte cell-cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukocyte tethering or rolling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of leukocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phosphatidylinositol 3-kinase signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cellular extravasation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of integrin activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to organic cyclic compound</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>